TherapeuticsMD
TXMD
42 hedge funds and large institutions have $3.09M invested in TherapeuticsMD in 2025 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 4 closing their positions.
600% more call options, than puts
Call options by funds: $14K | Put options by funds: $2K
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
2% more funds holding
Funds holding: 41 → 42 (+1)
2% more capital invested
Capital invested by funds: $3.03M → $3.09M (+$58.1K)
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
1.7% less ownership
Funds ownership: 30.61% → 28.9% (-1.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
+$13.1K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$3.16K |
| 3 |
Renaissance Technologies
New York
|
+$2.6K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$827 |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$723 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$145K |
| 2 |
TC
Tejara Capital
London,
United Kingdom
|
-$49.9K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$5.62K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$1.83K |
| 5 |
Morgan Stanley
New York
|
-$1.17K |
TXMD Hedge Fund Activity: Q1 2025 in Review
42 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q1 2025, worth a combined $3.09M — up 1.9% from $3.03M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new TXMD positions and 4 closed out — a net gain of 1 holder — while 7 added to existing stakes and 7 trimmed.
The largest buyer was Two Sigma Securities, opening a new position worth an estimated $13.1K. The largest seller was Citadel Advisors, exiting entirely with an estimated $145K sold.
- 42 institutional investors held TherapeuticsMD (TXMD) as of Q1 2025, up from 41 in Q4 2024.
- Funds reported $3.09M of TherapeuticsMD stock for Q1 2025, up 1.9% quarter-over-quarter.
- 5 funds opened new TherapeuticsMD positions in Q1 2025 and 4 closed out, a net change of +1 holder.
- The largest TherapeuticsMD buyer in Q1 2025 was Two Sigma Securities, an estimated $13.1K added.
- The largest TherapeuticsMD seller in Q1 2025 was Citadel Advisors, an estimated $145K sold.
Based on aggregated 13F filings for Q1 2025.